Advertisement
American Journal of Kidney Diseases

Therapeutic Strategies for Heart Failure in Cardiorenal Syndromes

      Cardiorenal syndromes are disorders of the heart and kidneys whereby acute or long-term dysfunction in one organ may induce acute or long-term dysfunction of the other. The management of cardiovascular diseases and risk factors may influence, in a beneficial or harmful way, kidney function and progression of kidney injury. In this review, we assess therapeutic strategies and discuss treatment options for the management of patients with heart failure with decreased kidney function and highlight the need for future high-quality studies in patients with coexisting heart and kidney disease.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Elsayed E.F.
        • Tighiouart H.
        • Griffith J.
        • et al.
        Cardiovascular disease and subsequent kidney disease.
        Arch Intern Med. 2007; 167: 1130-1136
        • Sarnak M.J.
        • Levey A.S.
        • Schoolwerth A.C.
        • et al.
        Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.
        Hypertension. 2003; 42: 1050-1065
        • Coca S.G.
        • Peixoto A.J.
        • Garg A.X.
        • Krumholz H.M.
        • Parikh C.R.
        The prognostic importance of a small acute decrement in kidney function in hospitalized patients: a systematic review and meta-analysis.
        Am J Kidney Dis. 2007; 50: 712-720
        • de Silva R.
        • Nikitin N.P.
        • Witte K.K.
        • et al.
        Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis.
        Eur Heart J. 2006; 27: 569-581
        • Damman K.
        • Jaarsma T.
        • Voors A.A.
        • et al.
        Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH).
        Eur J Heart Fail. 2009; 11: 847-854
        • Chittineni H.
        • Miyawaki N.
        • Gulipelli S.
        • Fishbane S.
        Risk for acute renal failure in patients hospitalized for decompensated congestive heart failure.
        Am J Nephrol. 2007; 27: 55-62
        • Krumholz H.M.
        • Chen Y.T.
        • Vaccarino V.
        • et al.
        Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure.
        Am J Cardiol. 2000; 85: 1110-1113
        • Smith G.L.
        • Vaccarino V.
        • Kosiborod M.
        • et al.
        Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?.
        J Card Fail. 2003; 9: 13-25
        • Forman D.E.
        • Butler J.
        • Wang Y.
        • et al.
        Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.
        J Am Coll Cardiol. 2004; 43: 61-67
        • Smith G.L.
        • Lichtman J.H.
        • Bracken M.B.
        • et al.
        Renal impairment and outcomes in heart failure: systematic review and meta-analysis.
        J Am Coll Cardiol. 2006; 47: 1987-1996
        • Shlipak M.G.
        • Massie B.M.
        The clinical challenge of cardiorenal syndrome.
        Circulation. 2004; 110: 1514-1517
        • Tang W.H.
        • Mullens W.
        Cardiorenal syndrome in decompensated heart failure.
        Heart. 2010; 96: 255-260
        • Liang K.V.
        • Williams A.W.
        • Greene E.L.
        • Redfield M.M.
        Acute decompensated heart failure and the cardiorenal syndrome.
        Crit Care Med. 2008; 36: S75-S88
        • Ronco C.
        • House A.A.
        • Haapio M.
        Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong.
        Intensive Care Med. 2008; 34: 957-962
        • Ronco C.
        • McCullough P.
        • Anker S.D.
        • et al.
        Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative.
        Eur Heart J. 2010; 31: 703-711
        • Bellomo R.
        • Ronco C.
        • Kellum J.A.
        • Mehta R.L.
        • Palevsky P.
        • Acute Dialysis Quality Initiative Workgroup
        Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.
        Crit Care. 2004; 8: R204-R212
        • Mehta R.L.
        • Kellum J.A.
        • Shah S.V.
        • et al.
        Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury.
        Crit Care. 2007; 11: R31
        • Adams Jr, K.F.
        • Fonarow G.C.
        • Emerman C.L.
        • et al.
        Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).
        Am Heart J. 2005; 149: 209-216
        • Nieminen M.S.
        • Brutsaert D.
        • Dickstein K.
        • et al.
        EuroHeart failure survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population.
        Eur Heart J. 2006; 27: 2725-2736
        • Hunt S.A.
        • Abraham W.T.
        • Chin M.H.
        • et al.
        2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation.
        J Am Coll Cardiol. 2009; 53: e1-e90
        • Jessup M.
        • Costanzo M.R.
        The cardiorenal syndrome: do we need a change of strategy or a change of tactics?.
        J Am Coll Cardiol. 2009; 53: 597-599
        • European Society of Cardiology, Heart Failure Association of the ESC (HFA), European Society of Intensive Care Medicine (ESICM), et al
        ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology.
        Eur J Heart Fail. 2008; 10: 933-989
        • Damman K.
        • Navis G.
        • Smilde T.D.
        • et al.
        Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction.
        Eur J Heart Fail. 2007; 9: 872-878
        • Mullens W.
        • Abrahams Z.
        • Skouri H.N.
        • et al.
        Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function?.
        J Am Coll Cardiol. 2008; 51: 300-306
        • Chen D.
        • Assad-Kottner C.
        • Orrego C.
        • Torre-Amione G.
        Cytokines and acute heart failure.
        Crit Care Med. 2008; 36: S9-S16
        • Smilde T.D.
        • Damman K.
        • van der Harst P.
        • et al.
        Differential associations between renal function and ”modifiable” risk factors in patients with chronic heart failure.
        Clin Res Cardiol. 2009; 98: 121-129
        • Ronco C.
        • Haapio M.
        • House A.A.
        • Anavekar N.
        • Bellomo R.
        Cardiorenal syndrome.
        J Am Coll Cardiol. 2008; 52: 1527-1539
        • Dries D.L.
        • Exner D.V.
        • Domanski M.J.
        • Greenberg B.
        • Stevenson L.W.
        The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.
        J Am Coll Cardiol. 2000; 35: 681-689
        • Ezekowitz J.
        • McAlister F.A.
        • Humphries K.H.
        • et al.
        The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease.
        J Am Coll Cardiol. 2004; 44: 1587-1592
        • Hillege H.L.
        • Nitsch D.
        • Pfeffer M.A.
        • et al.
        Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
        Circulation. 2006; 113: 671-678
        • Heywood J.T.
        • Fonarow G.C.
        • Costanzo M.R.
        • et al.
        High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database.
        J Card Fail. 2007; 13: 422-430
        • Tavazzi L.
        • Maggioni A.P.
        • Lucci D.
        • et al.
        Nationwide survey on acute heart failure in cardiology ward services in Italy.
        Eur Heart J. 2006; 27: 1207-1215
        • Lassus J.
        • Harjola V.P.
        • Sund R.
        • et al.
        Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP.
        Eur Heart J. 2007; 28: 1841-1847
        • Liu P.P.
        Cardiorenal syndrome in heart failure: a cardiologist's perspective.
        Can J Cardiol. 2008; 24: 25B-29B
        • Heywood J.T.
        The cardiorenal syndrome: lessons from the ADHERE database and treatment options.
        Heart Fail Rev. 2004; 9: 195-201
        • Shah R.V.
        • Givertz M.M.
        Managing acute renal failure in patients with acute decompensated heart failure: the cardiorenal syndrome.
        Curr Heart Fail Rep. 2009; 6: 176-181
        • Damman K.
        • Navis G.
        • Voors A.A.
        • et al.
        Worsening renal function and prognosis in heart failure: systematic review and meta-analysis.
        J Card Fail. 2007; 13: 599-608
        • Tojo A.
        • Onozato M.L.
        • Kobayashi N.
        • Goto A.
        • Matsuoka H.
        • Fujita T.
        Angiotensin II and oxidative stress in Dahl salt-sensitive rat with heart failure.
        Hypertension. 2002; 40: 834-839
        • Bonventre J.V.
        • Zuk A.
        Ischemic acute renal failure: an inflammatory disease?.
        Kidney Int. 2004; 66: 480-485
        • Bongartz L.G.
        • Cramer M.J.
        • Doevendans P.A.
        • Joles J.A.
        • Braam B.
        The severe cardiorenal syndrome: 'Guyton revisited'.
        Eur Heart J. 2005; 26: 11-17
        • Schrier R.W.
        Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?.
        J Am Coll Cardiol. 2006; 47: 1-8
        • Onozato M.L.
        • Tojo A.
        • Kobayashi N.
        • Goto A.
        • Matsuoka H.
        • Fujita T.
        Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney.
        Nephrol Dial Transplant. 2007; 22: 1314-1322
        • Nohria A.
        • Hasselblad V.
        • Stebbins A.
        • et al.
        Cardiorenal interactions: insights from the ESCAPE trial.
        J Am Coll Cardiol. 2008; 51: 1268-1274
        • Mullens W.
        • Abrahams Z.
        • Francis G.S.
        • et al.
        Importance of venous congestion for worsening of renal function in advanced decompensated heart failure.
        J Am Coll Cardiol. 2009; 53: 589-596
        • Uchino S.
        • Doig G.S.
        • Bellomo R.
        • et al.
        Diuretics and mortality in acute renal failure.
        Crit Care Med. 2004; 32: 1669-1677
        • Butler J.
        • Forman D.E.
        • Abraham W.T.
        • et al.
        Relationship between heart failure treatment and development of worsening renal function among hospitalized patients.
        Am Heart J. 2004; 147: 331-338
        • Metra M.
        • Nodari S.
        • Parrinello G.
        • et al.
        Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance.
        Eur J Heart Fail. 2008; 10: 188-195
        • Cowie M.R.
        • Komajda M.
        • Murray-Thomas T.
        • Underwood J.
        • Ticho B.
        • POSH Investigators
        Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the Prospective Outcomes Study in Heart Failure (POSH).
        Eur Heart J. 2006; 27: 1216-1222
        • Madkour H.
        • Gadallah M.
        • Riveline B.
        • Plante G.E.
        • Massry S.G.
        Comparison between the effects of indapamide and hydrochlorothiazide on creatinine clearance in patients with impaired renal function and hypertension.
        Am J Nephrol. 1995; 15: 251-255
        • den Uil C.A.
        • Lagrand W.K.
        • Spronk P.E.
        • et al.
        Low-dose nitroglycerin improves microcirculation in hospitalized patients with acute heart failure.
        Eur J Heart Fail. 2009; 11: 386-390
        • den Uil C.A.
        • Lagrand W.K.
        • Valk S.D.
        • Spronk P.E.
        • Simoons M.L.
        Management of cardiogenic shock: focus on tissue perfusion.
        Curr Probl Cardiol. 2009; 34: 330-349
        • Schulz V.
        • Bonn R.
        • Kindler J.
        Kinetics of elimination of thiocyanate in 7 healthy subjects and in 8 subjects with renal failure.
        Klin Wochenschr. 1979; 57: 243-247
        • Mullens W.
        • Abrahams Z.
        • Francis G.S.
        • et al.
        Sodium nitroprusside for advanced low-output heart failure.
        J Am Coll Cardiol. 2008; 52: 200-207
        • Reichert S.
        • Ignaszewski A.
        Molecular and physiological effects of nesiritide.
        Can J Cardiol. 2008; 24: 15B-18B
        • Sackner-Bernstein J.D.
        • Skopicki H.A.
        • Aaronson K.D.
        Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure.
        Circulation. 2005; 111: 1487-1491
        • Witteles R.M.
        • Kao D.
        • Christopherson D.
        • et al.
        Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial.
        J Am Coll Cardiol. 2007; 50: 1835-1840
        • Hernandez A.F.
        • O'Connor C.M.
        • Starling R.C.
        • et al.
        Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).
        Am Heart J. 2009; 157: 271-277
        • Cuffe M.S.
        • Califf R.M.
        • Adams Jr, K.F.
        • et al.
        Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial.
        JAMA. 2002; 287: 1541-1547
        • Felker G.M.
        • Benza R.L.
        • Chandler A.B.
        • et al.
        Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study.
        J Am Coll Cardiol. 2003; 41: 997-1003
        • Yilmaz M.B.
        • Yalta K.
        • Yontar C.
        • et al.
        Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine.
        Cardiovasc Drugs Ther. 2007; 21: 431-435
        • Mebazaa A.
        • Nieminen M.S.
        • Packer M.
        • et al.
        Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial.
        JAMA. 2007; 297: 1883-1891
        • Kirkby N.S.
        • Hadoke P.W.
        • Bagnall A.J.
        • Webb D.J.
        The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?.
        Br J Pharmacol. 2008; 153: 1105-1119
        • Coletta A.P.
        • Cleland J.G.
        Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology—WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME.
        Eur J Heart Fail. 2001; 3: 747-750
        • Bax J.J.
        • Casadei B.
        • Di Mario C.
        • et al.
        Highlights of the 2009 scientific sessions of the European Society of Cardiology.
        J Am Coll Cardiol. 2009; 54: 2447-2458
        • Gheorghiade M.
        • Konstam M.A.
        • Burnett Jr, J.C.
        • et al.
        Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials.
        JAMA. 2007; 297: 1332-1343
        • Coca S.G.
        • Krumholz H.M.
        • Garg A.X.
        • Parikh C.R.
        Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease.
        JAMA. 2006; 296: 1377-1384
        • Saltzman H.E.
        • Sharma K.
        • Mather P.J.
        • Rubin S.
        • Adams S.
        • Whellan D.J.
        Renal dysfunction in heart failure patients: what is the evidence?.
        Heart Fail Rev. 2007; 12: 37-47
        • McAlister F.A.
        • Ezekowitz J.
        • Tonelli M.
        • Armstrong P.W.
        Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study.
        Circulation. 2004; 109: 1004-1009
        • Hou F.F.
        • Zhang X.
        • Zhang G.H.
        • et al.
        Efficacy and safety of benazepril for advanced chronic renal insufficiency.
        N Engl J Med. 2006; 354: 131-140
        • Bakris G.L.
        • Weir M.R.
        Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?.
        Arch Intern Med. 2000; 160: 685-693
        • Shlipak M.G.
        Pharmacotherapy for heart failure in patients with renal insufficiency.
        Ann Intern Med. 2003; 138: 917-924
        • Knight E.L.
        • Glynn R.J.
        • McIntyre K.M.
        • Mogun H.
        • Avorn J.
        Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the Studies of Left Ventricular Dysfunction (SOLVD).
        Am Heart J. 1999; 138: 849-855
        • Pitt B.
        • Zannad F.
        • Remme W.J.
        • et al.
        The effect of spironolactone on morbidity and mortality in patients with severe heart failure.
        N Engl J Med. 1999; 341: 709-717
        • Pitt B.
        • Remme W.
        • Zannad F.
        • et al.
        Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
        N Engl J Med. 2003; 348: 1309-1321
        • Juurlink D.N.
        • Mamdani M.M.
        • Lee D.S.
        • et al.
        Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
        N Engl J Med. 2004; 351: 543-551
        • Ko D.T.
        • Juurlink D.N.
        • Mamdani M.M.
        • et al.
        Appropriateness of spironolactone prescribing in heart failure patients: a population-based study.
        J Card Fail. 2006; 12: 205-210
        • Yorgun H.
        • Deniz A.
        • Aytemir K.
        Cardiogenic shock secondary to combination of diltiazem and sotalol.
        Intern Med J. 2008; 38: 221-222
        • Fernandez J.S.
        • Sadaniantz A.
        Medical and revascularization management in acute coronary syndrome in renal patients.
        Semin Nephrol. 2001; 21: 25-35
        • Seiler K.U.
        • Schuster K.J.
        • Meyer G.J.
        • Niedermayer W.
        • Wassermann O.
        The pharmacokinetics of metoprolol and its metabolites in dialysis patients.
        Clin Pharmacokinet. 1980; 5: 192-198
        • Bakris G.L.
        • Hart P.
        • Ritz E.
        Beta blockers in the management of chronic kidney disease.
        Kidney Int. 2006; 70: 1905-1913
        • Baigent C.
        • Landray M.
        • Leaper C.
        • et al.
        First United Kingdom Heart and Renal Protection (UK-HARP-I) Study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
        Am J Kidney Dis. 2005; 45: 473-484
        • Keltai M.
        • Tonelli M.
        • Mann J.F.
        • et al.
        Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.
        Eur J Cardiovasc Prev Rehabil. 2007; 14: 312-318
        • Best P.J.
        • Steinhubl S.R.
        • Berger P.B.
        • et al.
        The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
        Am Heart J. 2008; 155: 687-693
        • Melloni C.
        • Peterson E.D.
        • Chen A.Y.
        • et al.
        Cockcroft-Gault versus Modification of Diet in Renal Disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes.
        J Am Coll Cardiol. 2008; 51: 991-996
        • Alexander K.P.
        • Chen A.Y.
        • Roe M.T.
        • et al.
        Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.
        JAMA. 2005; 294: 3108-3116
        • Silverberg D.S.
        • Wexler D.
        • Iaina A.
        • Steinbruch S.
        • Wollman Y.
        • Schwartz D.
        Anemia, chronic renal disease and congestive heart failure—the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists.
        Int Urol Nephrol. 2006; 38: 295-310
        • Fu P.
        • Arcasoy M.O.
        Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis.
        Biochem Biophys Res Commun. 2007; 354: 372-378
        • Riksen N.P.
        • Hausenloy D.J.
        • Yellon D.M.
        Erythropoietin: ready for prime-time cardioprotection.
        Trends Pharmacol Sci. 2008; 29: 258-267
        • Palazzuoli A.
        • Silverberg D.S.
        • Iovine F.
        • et al.
        Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome.
        Am Heart J. 2007; 154 (e9-15): 645
        • Ghali J.K.
        • Anand I.S.
        • Abraham W.T.
        • et al.
        Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia.
        Circulation. 2008; 117: 526-535
        • Locatelli F.
        • Pisoni R.L.
        • Combe C.
        • et al.
        Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
        Nephrol Dial Transplant. 2004; 19: 121-132
        • Singh A.K.
        • Szczech L.
        • Tang K.L.
        • et al.
        Correction of anemia with epoetin alfa in chronic kidney disease.
        N Engl J Med. 2006; 355: 2085-2098
        • Drueke T.B.
        • Locatelli F.
        • Clyne N.
        • et al.
        Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
        N Engl J Med. 2006; 355: 2071-2084
        • Pfeffer M.A.
        • Burdmann E.A.
        • Chen C.Y.
        • et al.
        A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.
        N Engl J Med. 2009; 361: 2019-2032
        • Besarab A.
        • Goodkin D.A.
        • Nissenson A.R.
        • Normal Hematocrit Cardiac Trial Authors
        The Normal Hematocrit Study—follow-up.
        N Engl J Med. 2008; 358: 433-434
        • Bolger A.P.
        • Bartlett F.R.
        • Penston H.S.
        • et al.
        Intravenous iron alone for the treatment of anemia in patients with chronic heart failure.
        J Am Coll Cardiol. 2006; 48: 1225-1227
        • Toblli J.E.
        • Lombrana A.
        • Duarte P.
        • Di Gennaro F.
        Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
        J Am Coll Cardiol. 2007; 50: 1657-1665
        • Usmanov R.I.
        • Zueva E.B.
        • Silverberg D.S.
        • Shaked M.
        Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency.
        J Nephrol. 2008; 21: 236-242
        • Okonko D.O.
        • Grzeslo A.
        • Witkowski T.
        • et al.
        Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
        J Am Coll Cardiol. 2008; 51: 103-112
        • Anker S.D.
        • Comin Colet J.
        • Filippatos G.
        • et al.
        Ferric carboxymaltose in patients with heart failure and iron deficiency.
        N Engl J Med. 2009; 361: 2436-2448
        • Wanner C.
        • Krane V.
        • Marz W.
        • et al.
        Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
        N Engl J Med. 2005; 353: 238-248
        • Fellstrom B.C.
        • Jardine A.G.
        • Schmieder R.E.
        • et al.
        Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
        N Engl J Med. 2009; 360: 1395-1407
        • Strippoli G.F.
        • Navaneethan S.D.
        • Johnson D.W.
        • et al.
        Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials.
        BMJ. 2008; 336: 645-651
        • Gray A.
        • Goodacre S.
        • Newby D.E.
        • et al.
        Noninvasive ventilation in acute cardiogenic pulmonary edema.
        N Engl J Med. 2008; 359: 142-151
        • Udani S.M.
        • Murray P.T.
        The use of renal replacement therapy in acute decompensated heart failure.
        Semin Dial. 2009; 22: 173-179
        • Libetta C.
        • Sepe V.
        • Zucchi M.
        • et al.
        Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines.
        Nephrol Dial Transplant. 2007; 22: 2013-2019
        • Bart B.A.
        • Boyle A.
        • Bank A.J.
        • et al.
        Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial.
        J Am Coll Cardiol. 2005; 46: 2043-2046
        • Costanzo M.R.
        • Guglin M.E.
        • Saltzberg M.T.
        • et al.
        Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.
        J Am Coll Cardiol. 2007; 49: 675-683
        • Boerrigter G.
        • Costello-Boerrigter L.C.
        • Abraham W.T.
        • et al.
        Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate.
        J Card Fail. 2008; 14: 539-546
        • Tokunaga S.
        • Tominaga R.
        • Nakano T.
        • Fukae K.
        • Takeshita A.
        • Yasui H.
        Effects of intra-aortic balloon pumping on renal sympathetic nerve activity and renal circulation in dogs.
        J Cardiovasc Surg (Torino). 2000; 41: 669-674
        • Norkiene I.
        • Ringaitiene D.
        • Rucinskas K.
        • et al.
        Intra-aortic balloon counterpulsation in decompensated cardiomyopathy patients: bridge to transplantation or assist device.
        Interact Cardiovasc Thorac Surg. 2007; 6: 66-70
        • Butler J.
        • Geisberg C.
        • Howser R.
        • et al.
        Relationship between renal function and left ventricular assist device use.
        Ann Thorac Surg. 2006; 81: 1745-1751
        • Roussel J.C.
        • Senage T.
        • Baron O.
        • et al.
        CardioWest (Jarvik) total artificial heart: a single-center experience with 42 patients.
        Ann Thorac Surg. 2009; 87 (discussion 130): 124-129
        • McCullough P.A.
        Cardiorenal risk: an important clinical intersection.
        Rev Cardiovasc Med. 2002; 3: 71-76
        • Wright R.S.
        • Reeder G.S.
        • Herzog C.A.
        • et al.
        Acute myocardial infarction and renal dysfunction: a high-risk combination.
        Ann Intern Med. 2002; 137: 563-570
        • Beattie J.N.
        • Soman S.S.
        • Sandberg K.R.
        • et al.
        Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction.
        Am J Kidney Dis. 2001; 37: 1191-1200
        • Gibson C.M.
        • Pinto D.S.
        • Murphy S.A.
        • et al.
        Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality.
        J Am Coll Cardiol. 2003; 42: 1535-1543
        • Berger A.K.
        • Duval S.
        • Krumholz H.M.
        Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction.
        J Am Coll Cardiol. 2003; 42: 201-208